Literature DB >> 9436304

Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa.

M Ghani1, J S Soothill.   

Abstract

In continuous flow biofilm cultures in medium resembling cystic fibrosis bronchial secretions, Pseudomonas aeruginosa was not eradicated from biofilms by 1 week of treatment with high concentrations of ceftazidime and gentamicin, to which the strains were sensitive on conventional testing. The addition of rifampicin, which has little activity against the strains as measured by the minimum inhibitory concentration, led to the apparent elimination of the bacteria from the biofilms. The effect was not strain specific.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436304     DOI: 10.1139/m97-144

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  16 in total

1.  Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus.

Authors:  Ute Schwab; Lubna H Abdullah; Olivia S Perlmutt; Daniel Albert; C William Davis; Roland R Arnold; James R Yankaskas; Peter Gilligan; Heiner Neubauer; Scott H Randell; Richard C Boucher
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Coexistence in the chemostat as a result of metabolic by-products.

Authors:  Julia Hesseler; Julia K Schmidt; Udo Reichl; Dietrich Flockerzi
Journal:  J Math Biol       Date:  2006-07-04       Impact factor: 2.259

Review 3.  Physicochemical properties of mucus and their impact on transmucosal drug delivery.

Authors:  Jasmim Leal; Hugh D C Smyth; Debadyuti Ghosh
Journal:  Int J Pharm       Date:  2017-09-14       Impact factor: 5.875

4.  Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum.

Authors:  Nicholas S Britt; Daniel S Hazlett; Rebecca T Horvat; Rachael M Liesman; Molly E Steed
Journal:  Int J Antimicrob Agents       Date:  2020-01-11       Impact factor: 5.283

5.  Activity of Antibiotics against Staphylococcus aureus in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Authors:  Yvan Diaz Iglesias; Tobias Wilms; Rita Vanbever; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

6.  Unpredictable effects of rifampin as an adjunctive agent in elimination of rifampin-susceptible and -resistant Staphylococcus aureus strains grown in biofilms.

Authors:  Sander Croes; Patrick S Beisser; Cees Neef; Cathrien A Bruggeman; Ellen E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

7.  Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum.

Authors:  Kelli L Palmer; Lindsay M Aye; Marvin Whiteley
Journal:  J Bacteriol       Date:  2007-09-14       Impact factor: 3.490

8.  In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.

Authors:  Qianru Yu; Edward F Griffin; Sophie Moreau-Marquis; Joseph D Schwartzman; Bruce A Stanton; George A O'Toole
Journal:  J Antimicrob Chemother       Date:  2012-07-26       Impact factor: 5.790

9.  Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Authors:  Yvan Diaz Iglesias; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

10.  Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Authors:  Yan Yang; Michael D Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt; Yoon Yeo
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.